Katsuyuki Takeda Selected Research

Interleukin-13

1/2019	Hypoxia enhances CD8+ TC2 cell-dependent airway hyperresponsiveness and inflammation through hypoxia-inducible factor 1α.
2/2015	Eosinophils contribute to the resolution of lung-allergic responses following repeated allergen challenge.
7/2014	Effects of anti-g and anti-f antibodies on airway function after respiratory syncytial virus infection.
3/2014	Leukotriene B4 receptor 1 is differentially expressed on peripheral T cells of steroid-sensitive and -resistant asthmatics.
5/2013	Steroidogenic enzyme Cyp11a1 regulates Type 2 CD8+ T cell skewing in allergic lung disease.
8/2010	Peanut-induced intestinal allergy is mediated through a mast cell-IgE-FcepsilonRI-IL-13 pathway.
9/2009	Differential effects of dendritic cell transfer on airway hyperresponsiveness and inflammation.
6/2009	Leukotriene B4 release from mast cells in IgE-mediated airway hyperresponsiveness and inflammation.
1/2009	Mitogen-activated protein kinase/extracellular signal-regulated kinase 1/2-dependent pathways are essential for CD8+ T cell-mediated airway hyperresponsiveness and inflammation.
1/2009	Virus-specific IgE enhances airway responsiveness on reinfection with respiratory syncytial virus in newborn mice.

For more, sign up at right for free...

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Katsuyuki Takeda Research Topics

Disease

62	Inflammation (Inflammations) 01/2022 - 07/2002
57	Respiratory Hypersensitivity 01/2022 - 07/2002
22	Eosinophilia 06/2016 - 07/2002
21	Asthma (Bronchial Asthma) 01/2022 - 07/2002
13	Metaplasia 06/2016 - 01/2006
8	Pneumonia (Pneumonitis) 02/2015 - 07/2002
7	Infections 07/2014 - 12/2003
7	Hyperplasia 05/2006 - 11/2002
5	Reinfection 07/2014 - 08/2005
4	Hypersensitivity (Allergy) 01/2018 - 08/2010
4	Respiratory Syncytial Virus Infections 07/2014 - 12/2003
3	Allergic Rhinitis 01/2013 - 11/2005
2	Emphysema 07/2021 - 01/2018
2	Lung Diseases (Lung Disease) 05/2013 - 01/2011
2	Neoplasms (Cancer) 05/2012 - 09/2003
2	Respiratory Distress Syndrome (Acute Respiratory Distress Syndrome) 09/2009 - 09/2003
2	Acute Lung Injury 09/2009 - 09/2003
2	Nasal Obstruction 11/2006 - 11/2005
1	Hypoxia (Hypoxemia) 01/2019
1	Respiratory Sounds (Crackle) 03/2018
1	Diarrhea 01/2018
1	Peanut Hypersensitivity (Peanut Allergy) 01/2018
1	Chronic Obstructive Pulmonary Disease (COPD) 06/2016
1	Necrosis 05/2012
1	Coinfection 08/2010
1	Respiratory Tract Diseases (Respiratory Tract Disease) 08/2010

Drug/Important Bio-Agent (IBA)

42	AllergensIBA 01/2022 - 07/2002
32	CytokinesIBA 04/2017 - 07/2002
29	Interleukin-13IBA 01/2019 - 12/2002
20	Methacholine Chloride (Methacholine)FDA Link 01/2022 - 07/2002
13	Immunoglobulin E (IgE)IBA 01/2022 - 07/2002
9	OvalbuminIBA 06/2016 - 07/2002
8	Interleukin-4 (Interleukin 4)IBA 01/2019 - 02/2004
8	Leukotriene B4IBA 03/2014 - 04/2005
8	InterleukinsIBA 01/2006 - 10/2003
7	Proteins (Proteins, Gene)FDA Link 07/2021 - 09/2003
7	Interleukin-5 (Interleukin 5)IBA 02/2015 - 12/2003
5	Leukotriene B4 Receptors (Leukotriene B4 Receptor)IBA 03/2014 - 07/2005
4	Adrenal Cortex Hormones (Corticosteroids)IBA 01/2019 - 04/2008
4	Interleukin-10 (Interleukin 10)IBA 02/2015 - 02/2007
4	AntigensIBA 01/2012 - 02/2004
3	Immunoglobulin G (IgG)IBA 07/2021 - 12/2003
3	SteroidsIBA 01/2019 - 03/2014
3	Messenger RNA (mRNA)IBA 01/2018 - 11/2004
3	Complement System Proteins (Complement)IBA 01/2012 - 12/2003
3	OzoneIBA 04/2009 - 03/2004
3	IgE Receptors (Fc epsilon RI)IBA 01/2009 - 05/2004
2	Interleukin-2 (IL2)IBA 01/2019 - 03/2007
2	Surface-Active Agents (Surfactants)IBA 06/2016 - 09/2003
2	Cholesterol Side-Chain Cleavage Enzyme (CYP11A1)IBA 01/2016 - 05/2013
2	AntibodiesIBA 07/2014 - 11/2004
2	InterferonsIBA 03/2014 - 09/2005
2	Interleukin-12 (IL 12)IBA 11/2012 - 10/2003
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 10/2012 - 11/2002
2	ChemokinesIBA 08/2011 - 01/2006
2	Interleukin-6 (Interleukin 6)IBA 01/2011 - 08/2010
2	LeukotrienesIBA 08/2010 - 06/2006
2	LipidsIBA 09/2009 - 06/2009
2	Small Interfering RNA (siRNA)IBA 09/2009 - 01/2008
2	Interleukin-18 (Interleukin 18)IBA 03/2007 - 06/2004
2	Chemokine CCL5IBA 08/2006 - 01/2006
2	aluminum sulfate (alum)IBA 04/2006 - 01/2006
2	Interleukin-1 (Interleukin 1)IBA 06/2004 - 06/2004
2	Pulmonary Surfactant-Associated Protein D (Surfactant Protein D)IBA 10/2003 - 09/2003
2	Histamine Antagonists (Antihistamines)IBA 10/2003 - 07/2002
2	fexofenadine (Allegra)FDA LinkGeneric 10/2003 - 07/2002
1	Pancreatic Elastase (Elastase)IBA 07/2021
1	SmokeIBA 07/2021
1	Oxygen (Dioxygen)IBA 01/2019
1	Janus Kinase 1IBA 01/2019
1	Cromolyn Sodium (Cromoglicic Acid)FDA LinkGeneric 03/2018
1	Beclomethasone (Beclometasone)FDA Link 03/2018
1	Tretinoin (Retinoic Acid)FDA LinkGeneric 01/2018
1	Forkhead Transcription Factors (Forkhead Box Proteins)IBA 01/2018
1	Ambroxol (Mucosolvan)IBA 06/2016
1	AntioxidantsIBA 06/2016
1	Monoclonal AntibodiesIBA 07/2014
1	Glycoproteins (Glycoprotein)IBA 07/2014
1	Cytokine Receptors (Cytokine Receptor)IBA 04/2014
1	EnzymesIBA 05/2013
1	Aminoglutethimide (Cytadren)FDA Link 05/2013
1	Histamine (Histamine Dihydrochloride)FDA Link 01/2013
1	JNK Mitogen-Activated Protein KinasesIBA 05/2012
1	GlucocorticoidsIBA 05/2012
1	Phosphotransferases (Kinase)IBA 04/2012
1	Protein Serine-Threonine Kinases (Protein-Serine-Threonine Kinase)IBA 04/2012
1	proto-oncogene proteins pimIBA 04/2012
1	Complement 3d Receptors (Complement Receptor 2)IBA 01/2012
1	Complement C3b (C3bi)IBA 01/2012
1	Complement Factor H (Factor H)IBA 01/2012
1	EndotoxinsIBA 01/2012
1	Chemokine ReceptorsIBA 08/2011
1	montelukast (Singulair)FDA Link 08/2010
1	Interleukin-13 Receptor alpha2 SubunitIBA 08/2010
1	LipopolysaccharidesIBA 09/2009
1	VaccinesIBA 07/2009

Therapy/Procedure

5	Therapeutics 03/2018 - 09/2005
2	Ligation 05/2012 - 01/2009
2	Intranasal Administration 01/2008 - 05/2006
2	Aftercare (After-Treatment) 03/2007 - 10/2003